-
Guizhou bailing anti hepatitis a new drug tifentai Y101 obtained clinical approval
Time of Update: 2020-04-03
Tefentai tablet is a kind of new chemical medicine against hepatitis B, and it is a major new drug creation project in the 12th Five Year Plan, Guizhou bailing has undertaken a total of 30 million yua
-
[in depth inventory] up to now, there are only 10 kinds of domestic monoclonal antibodies approved by CFDA for listing
Time of Update: 2020-04-03
In 1986, OKT3, the world's first monoclonal antibody drug for the treatment of rejection in organ transplantation, was approved by the US FDA, which started the development of monoclonal antibody drug
-
Silitan, a new antihypertensive drug of xinlitai, plans to carry out overseas registration and clinical work
Time of Update: 2020-04-03
Xinlitai (Ye Yuxiang, general manager, said at the performance briefing today that the company's new product, xinlitan (alisartan ester tablets), is a global innovative product At present, it has obta
-
The unveiling ceremony of the State Key Laboratory of innovative drugs and efficient energy saving pharmaceutical equipment was held in Jiangzhong group
Time of Update: 2020-04-03
On the morning of November 28, the unveiling ceremony of the State Key Laboratory of innovative drugs and efficient energy saving and consumption reducing pharmaceutical equipment was held in Jiangzho
-
Review of new approvals for the first quarter of 2015
Time of Update: 2020-04-03
The approvals issued so far this month include 198 chemicals, 386 traditional Chinese medicines and 13 biological products This month, a large number of TCM approvals were issued, all of which were non new In addition, the editor analyzed the differences between the drugs approved by CFDA in the first quarter of this year and last year Is the approval speed faster than last year?
-
Sichuan chuanshegan flavone capsule and Ranjiangduoji capsule obtained the production approval
Time of Update: 2020-04-03
Recently, chuanshegan flavone capsule and Ranjiangduoji capsule, two kinds of traditional Chinese medicine, have been approved by the State Administration, breaking through the situation that no new t
-
Approved production of Zhifei biological typhoid Vi polysaccharide vaccine
Time of Update: 2020-04-03
According to the information on June 18 on the website of the State Food and Drug Administration (CFDA), the production approval of typhoid Vi polysaccharide vaccine declared by Beijing green bamboo b
-
New drug research and development progress disclosed by Northeast Pharmaceutical
Time of Update: 2020-04-03
Zhang Zhengwei, financial director of Northeast Pharmaceutical, stressed in the dingzeng roadshow that the company is now gradually completing the transformation from API to pharmaceutical industry ch
-
Huadong Pharmaceutical Group 3.1 antifungal drug kapofungin acetate applied for production accepted
Time of Update: 2020-04-03
According to the information on April 3 on the website of the State Food and Drug Administration (CFDA), the application for the production of 3.1 antifungal drug kapofen acetate was accepted Accordin
-
"Microecological new drug project" of Donghai pharmaceutical won the first prize of Qingdao technology invention
Time of Update: 2020-04-03
Qingdao Donghai Pharmaceutical Co., Ltd has experienced 8 years of painstaking research and development of a series of micro ecological new drug projects Recently, it has successfully realized industr
-
Clinical approval of pegylated recombinant human interferon α 2B injection in Anke
Time of Update: 2020-04-03
On the evening of May 22, an kebio announced that the company's self-developed and characteristic pegylated recombinant human interferon α 2B injection was approved by the State Food and Drug Administ
-
Tonghua Dongbao third generation insulin, insulin glargine, received the information of hair and tonic
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on April 4, the third generation of Tonghua Dongbao insulin "insulin glargine" and "insulin glargine injection" reported clini
-
Clinical approval of yizhemeb tablets
Time of Update: 2020-04-03
Approval document for clinical trials of drugs (SH: 600422): Announcement on obtaining the approval document for clinical trials of yizheimai tablets Recently, kunyao Group Co., Ltd (hereinafter refer
-
Lenalidomide preparation of Shuanglu pharmaceutical industry has been applied for production
Time of Update: 2020-04-03
Shuanglu Pharmaceutical (002038 SZ) said on the interactive platform that lenalidomide preparation had recently been declared for production According to the website of the State Food and Drug Adminis
-
Another new indication of nerve growth factor in Shandong unnamed mice is approved
Time of Update: 2020-04-03
Drug clinical trial approval document (SZ: 002581): Notice on obtaining drug clinical trial approval document Shandong Weiming biomedical Co., Ltd., a wholly-owned subsidiary of Shandong Weiming biome
-
Fosun medicine transfers two new drugs of type II diabetes and tumor to sellas
Time of Update: 2020-04-03
As a leading pharmaceutical listed company in China, Fosun Pharmaceutical has made important progress in R & D and innovation On October 23, 2013, Chongqing fuchuang Pharmaceutical Research Co., Ltd (
-
Huahai Pharmaceutical Co., Ltd.'s withdrawal of 8 drug applications
Time of Update: 2020-04-03
A notice issued by the General Administration of drugs on the 26th once again pushed Huahai Pharmaceutical (600521) to the forefront of the wave Huahai pharmaceutical shares fell 4.41% on the 27th In
-
Chongqing Zhien Pharmaceutical Co., Ltd. "mesylate", the first imitated drug in the treatment of bronchial asthma, has obtained the new drug certificate
Time of Update: 2020-04-03
The raw materials and granules of mesilast, a drug for treating bronchial asthma, developed by Chongqing Zhien Pharmaceutical Co., Ltd., obtained the new drug certificate and production approval issue
-
Adenosylmethionine succinate, a new hepatobiliary drug from Zhenyuan, Zhejiang Province, is expected to obtain production approval in the first half of the year
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on March 20, the three in one review of adenosylmethionine succinate bulk drug and injection, a new hepatobiliary drug declare
-
Ivertinib, the original drug of Essen medicine, has initial clinical effect and breaks through the difficult problem of targeted treatment of lung cancer
Time of Update: 2020-04-03
300mg is the best effective dose, and the effective rate of lung cancer focus reduction is more than 50% This is the latest progress of the first original third generation EGFR (epidermal growth facto
